A182400 logo

NKMAX CO., Ltd. Stock Price

KOSDAQ:A182400 Community·₩172.7b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

A182400 Share Price Performance

₩0
0.00 (0.00%)
₩0
0.00 (0.00%)
Price ₩0

A182400 Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Slightly overvalued with questionable track record.

3 Risks
2 Rewards

NKMAX CO., Ltd. Key Details

₩10.5b

Revenue

₩3.4b

Cost of Revenue

₩7.1b

Gross Profit

-₩8.6b

Other Expenses

₩15.6b

Earnings

Last Reported Earnings
Mar 31, 2024
Next Reporting Earnings
n/a
182.94
67.40%
149.35%
22.8%
View Full Analysis

About A182400

Founded
2002
Employees
134
CEO
Sangwoo Park
WebsiteView website
www.nkmax.com

NKMAX CO., Ltd. manufactures and sells biological products in South Korea. The company offers anti-cancer immunotherapy treatment that activates the immune cells in body to kill the cancer cells; natural killer cell activity test for cancer patients; NK VUE Kit, an NK cell activity test that measures IFN-gamma released from activated NK cells with small amount of blood; and NK365, a proprietary blend of vitamins, minerals, and agaricus mushroom extract for immune system. It also provides recombinant proteins and monoclonal antibodies; and NK PUPPY, a test that measures dog’s immunity. The company was formerly known as ATGen Co and changed name to NKMAX CO., Ltd. in 2019. The company was founded in 2002 and is headquartered in Seongnam-si, South Korea.

Recent A182400 News & Updates

Recent updates

No updates